To determine whether joint CETP and SGLT2 inhibition has an impact on diabetes risk within each of our groups, we leverage the same analytical framework as detailed above for glycated hemoglobin but use Cox proportional hazards modelling instead of linear regression. This evidence concerns the gene SLC5A2 and diabetes mellitus.